Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular genetic characterization of tamoxifen-associated endometrial cancer.

Gynecologic oncology - 1 Jan 2005

Prasad Monica, Wang Hong, Douglas Wayne, Barakat Richard R, Ellenson Lora Hedrick

Abstract excerpt

OBJECTIVES: The non-steroidal, selective estrogen receptor modulator tamoxifen is currently the most extensively used hormonal agent for the prevention and treatment of estrogen receptor-positive breast cancer. Epidemiologic studies and clinical trials have shown an increased risk of endometrial cancer with tamoxifen exposure; however, few studies have examined these tumors on a molecular level. We sought to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Endometrioid
Share to Cocarcinogenesis
Share to Endometrial Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms, Second Primary

Share to Phosphoric Monoester Hydrolases

Share to PTEN Phosphohydrolase

Share to Selective Estrogen Receptor Modulators

Share to Tamoxifen

Source

Identifiers

PMID: 15589576
DOI: 10.1016/j.ygyno.2004.08.046

Genes

PTEN
CTNNB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular genetic characterization of tamoxifen-associated endometrial cancer.PMID 15589576Read ↗

Endometrial carcinoma in tamoxifen-treated breast cancer patient: clinicopathological, immunohistochemical, and genetic analysis.Semantic proximity Read ↗

Evaluation of germline PTEN mutations in endometrial cancer patients.Semantic proximity Read ↗

Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.Semantic proximity Read ↗

MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases.Semantic proximity Read ↗

Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints.Semantic proximity Read ↗

Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma.Semantic proximity Read ↗

Molecular basis of endometrial cancerSemantic proximity Read ↗

Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies.Semantic proximity Read ↗

Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomasSemantic proximity Read ↗

Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations.Semantic proximity Read ↗

Molecular pathogenesis of endometrial cancers in patients with Lynch syndromeSemantic proximity Read ↗

Effects of tamoxifen on the endometrium and its mechanism of carcinogenicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.